Boehringer Ingelheim GmbH
Ute E. Schmidt
Results of 5,993 patient study UPLIFT® (Understanding Potential Long-term Impacts on Function with Tiotropium) presented today at European Respiratory Society Annual Congress
For medical media, outside the US only
Berlin/Germany, 5 Oct. 2008 - Results of the UPLIFT® trial, presented today at the European Respiratory Society (ERS) Annual Congress, demonstrated that tiotropium (Spiriva®) administered to Chronic Obstructive Pulmonary Disease (COPD) patients, showed sustained improvements in lung function for up to 4 years (p<0.001), although it did not alter the rate of decline in lung function. The landmark study also reaffirmed the favourable safety profile of tiotropium.
UPLIFT ®also demonstrated that tiotropium produced a significant delay in time to first exacerbation by a median of 4.1 months (p<0.001), a significant reduction in the number of exacerbations per patient year (14%; p<0.001). In addition, it significantly reduced the risk of exacerbations leading to hospitalisations (Hazard Ratio 0.86; p<0.002) versus the control group. Exacerbations can worsen the clinical course of the disease, so a treatment that significantly reduces exacerbations can positively impact the clinical course of COPD.2
UPLIFT®, one of the largest COPD trials ever undertaken, involved 5,993 COPD patients from 37 countries around the globe. UPLIFT® is a landmark COPD trial comparing tiotropium 18 µg once daily with placebo, and allowed all patients to continue with their normally prescribed respiratory medications, including dose adjustments throughout the trial, except inhaled anticholinergics.
Tiotropium also provided statistically significant improvements in health-related quality of life, as measured by the St. George’s Respiratory Questionnaire (SGRQ, p<0.001).*
Throughout the four-year trial period, patients in the tiotropium group consistently reported a better quality of life than at study initiation.
Further, a statistically significant 16% decrease in the risk of death (p=0.016) was observed in the tiotropium group, while patients received treatment. Within the four year treatment period of the trial, the effect on survival was sustained, even when deaths occurring after early discontinuation of study medication were included in the analysis (p=0.034). Risk of mortality was assessed for the 30 days following the conclusion of the treatment period, and the study revealed an 11% reduced risk of death, although it did not meet statistical significance (p=0.086).
Importantly, tiotropium reduced respiratory (p<0.05) and cardiac morbidity (p<0.05), which reaffirms the favourable safety profile of tiotropium. As in previous studies the most commonly observed side effect was dry mouth.
Professor Marc Decramer, lead investigator and Professor of Medicine at the Catholic University Hospital in Leuven, Belgium said: “UPLIFT® faced a considerable challenge to demonstrate treatment benefits – unlike most other respiratory trials; it allowed all patients to be treated with all other concomitant respiratory medications, except for inhaled anticholinergics. In UPLIFT®, tiotropium performed very well over the long term by improving survival rates, lung function, exacerbation rates, and patients’ quality of life, while also confirming its favourable safety profile. The UPLIFT® data adds to the growing knowledge of how treatment can impact the clinical course of COPD. This will allow physicians to prescribe a long-term maintenance treatment early on with confidence.”
The data also demonstrate that tiotropium provides important benefits in moderate disease severity patients (GOLD-Global Initiative for Chronic Obstructive Lung Disease– Stage II).1 Forty-six percent of the patients in the UPLIFT® trial were GOLD Stage II. This is one of the largest COPD Stage II patient populations ever studied over four years. The results obtained for this patient group are especially relevant as this is the stage when patients normally first seek treatment for COPD symptoms.
“The results from UPLIFT® are good news, especially for primary care physicians who are usually the first medical contact a patient has once they decide to seek treatment. UPLIFTâ provides the confidence that treatment benefits of tiotropium are sustained long-term, and COPD patients can lead more active lives for longer,” said Dr. Anders Østrem, MD, Specialist in Family Medicine, Oslo, Norway and past President of International Primary Care Respiratory Group.
UPLIFT® proves tiotropium sustains positive effects for patients with COPD. “Patients report feeling better and the benefit seen in survival rates offers more hope to patients, their families, and their physicians,” commented Dr Andreas Barner, Vice Chairman of the Board of Managing Directors at Boehringer Ingelheim, responsible for Research, Development and Medicine. “Most importantly, the four-year study highlights the favourable safety profile of tiotropium. Almost 6,000 patients were followed for up to four years, adding to the more than 10 million patient years of market experience for Spiriva®.”
Notes to Editors:
COPD is a progressive yet treatable disease that restricts patients’ lives over time and is a major cause of death and disability throughout the world. Symptoms include cough, sputum (mucus or phlegm) production, and breathlessness on exertion. Worsening of these symptoms often occurs and can restrict a patient’s ability to perform normal daily activities.1 The latest World Health Organization (WHO) figures estimate that 210 million people are currently living with COPD and more than 3 million people died from the disease in 20052 - more than breast cancer and diabetes combined.3 Dyspnoea (breathlessness), the main symptom of COPD, is characteristically persistent and progressive and has a serious impact on patients’ quality of life.1 At its most severe, it even limits a patient from simple tasks such as washing and dressing.
UPLIFT® Study Design
The four-year study was a multicentre (470 sites), multinational (37 countries), randomised, double-blind, placebo-controlled, parallel-group trial which commenced in December 2002. The study included 5993 male and female COPD patients. Patients were randomised 1:1 to receive either 18 μg tiotropium or placebo once daily. In both arms, patients were allowed to take all other respiratory medications usually prescribed for the treatment of COPD, except for inhaled anticholinergics.
About tiotropium (Spiriva®)
Tiotropium, a long-acting inhaled anticholinergic medication, is the first inhaled treatment to provide significant and sustained improvements in lung function with once-daily dosing. Tiotropium positively impacts the clinical course of COPD, helping to change the way patients live with their disease.4,5 It is the most prescribed medication for the treatment of COPD in the world.
Tiotropium works through targeting of a dominant reversible mechanism of COPD – cholinergic bronchoconstriction. Tiotropium helps COPD patients breathe easier by opening narrowed airways and helping to keep them open for 24 hours.
Tiotropium has demonstrated significant and sustained bronchodilation (opening of the airways)6 and reduction in hyperinflation (air trapping).7,8 Tiotropium also demonstrated superior and sustained improvements in lung function (FEV1) over ipratropium bromide (Atrovent®) Inhalation Aerosol, a current first-line therapy for COPD, which were maintained over one year5 and has also demonstrated superior improvement in key lung function parameters over salmeterol.9 In addition, in placebo-controlled studies, patients treated with tiotropium had less activity-induced breathlessness and improved exercise endurance. They required fewer doses of rescue medications, had fewer exacerbations and COPD-related hospitalizations.6 In clinical trials, the most common adverse reaction reported with tiotropium was dry mouth, which was usually mild and often resolved spontaneously during treatment.6 Long-acting bronchodilators, including tiotropium, are a preferred maintenance therapy for COPD from stage II onwards according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) treatment guidelines.1
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and 39,800 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2007, Boehringer Ingelheim posted net sales of 10.9 billion Euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development.
About Pfizer Inc
Founded in 1849, Pfizer is the world`s largest research-based pharmaceutical company taking new approaches to better health. We discover, develop, manufacture and deliver quality, safe and effective prescription medicines to treat and help prevent disease for both people and animals. We also partner with healthcare providers, governments and local communities around the world to expand access to our medicines and to provide better quality health care and health system support. At Pfizer, more than 80,000 colleagues in more than 90 countries work every day to help people stay happier and healthier longer and to reduce the human and economic burden of disease worldwide
*Health-related quality of life was evaluated using the Saint George’s Respiratory Questionnaire (SGRQ), where a four-point decrease in SGRQ score is considered to be a clinically meaningful improvement in a patient’s health-related quality of life. Webcast and additional media materials.
|page||03 September 2012 COPD|
|page||03 September 2012 Spiriva|
|page||15 June 2011 COPD|
1 Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: http://www.goldcopd.com/Guidelineitem.asp?l1=2&l2=1&intId=989 Updated: 2007
2 Source: World Health Report. World Health Organization. Available from URL: http://www.who.int/respiratory/copd/en/
3 World Health Organization. World Health Report 2004. Statistical Annex. Annex table 2 and 3: 120-131.
4 Casaburi R, Kukafka D, Cooper CB, et al. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005; 127:809-817.
5 Vincken W, van Noord JA, Greefhorst APM, et al. Improved health outcomes in patients with COPD during 1 year’s treatment with tiotropium. Eur Respir J 2002; 19:209-216.
6 Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002; 1:217-224.
7 Celli B, ZuWallack R, Wang S, et al. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124: 1743-1748.
8 O`Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004 23(6):832-48
9 Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice